title: Thoracic perfusion of matrine as an adjuvant treatment improves the control of the malignant pleural effusions.
abstract: BACKGROUND
  Many studies have investigated the efficacy and safety of matrine in treating malignant pleural effusion by thoracic perfusion. This study is an analytic value of available evidence.
  
  
  METHODS
  Twelve studies were analyzed in this study. Pooled odds ratios and hazard ratio with 95 % confidence intervals were calculated using the fixed effects model.
  
  
  RESULTS
  Overall response rate of matrine combined with other medications in treating malignant pleural effusion (MPE) was significantly higher than those of other medications alone (p < 0.05). Time to pleural effusion relief and quality of life were improved after the treatment of matrine combined with other medications (p < 0.05). Moreover, matrine combined with other medications had a lower incidence of adverse reactions (p < 0.05).
  
  
  CONCLUSIONS
  Matrine combined with other medications improves the control of the malignant pleural effusions and decreases the incidence of adverse reactions.
authors.affiliation: Department of Respiratory Medicine, The Second Affiiated Hospital, Xi'an Jiaotong University, Xi'an, China.
authors.forename: Rong
authors.initials: R
authors.lastname: Biaoxue
authors.affiliation: Department of Elderly Respiratory Medicine, The Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
authors.forename: Ma
authors.initials: M
authors.lastname: Shuxia
authors.affiliation: Department of Statistics and Epidemiology, Medical College, Lanzhou University, Lanzhou, China.
authors.forename: Gao
authors.initials: G
authors.lastname: Wenlong
authors.affiliation: Department of Respiratory Medicine, The Second Affiiated Hospital, Xi'an Jiaotong University, Xi'an, China. yangshuanying66@163.com.
authors.forename: Yang
authors.initials: Y
authors.lastname: Shuanying
mesh_terms: D000470:Alkaloids / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D006801:Humans; D008175:Lung Neoplasms / Q000517:prevention & control*; D015201:Meta-Analysis as Topic; D010477:Perfusion; D016066:Pleural Effusion, Malignant / Q000517:prevention & control*; D011379:Prognosis; D011788:Quality of Life; D011807:Quinolizines / Q000627:therapeutic use*; D000093842:Matrines
chemical_list: D000470:Alkaloids; D011807:Quinolizines; D000093842:Matrines